Your browser doesn't support javascript.
loading
Seasonal variations for newly prescribed urate-lowering drugs for asymptomatic hyperuricemia and gout in Japan.
Kurajoh, Masafumi; Akari, Seigo; Nakamura, Takashi; Ihara, Yasutaka; Imai, Takumi; Morioka, Tomoaki; Emoto, Masanori.
Affiliation
  • Kurajoh M; Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
  • Akari S; Medical Affairs Department, Sanwa Kagaku Kenkyusho Co., Ltd., Nagoya, Aichi, Japan.
  • Nakamura T; Medical Affairs Department, Sanwa Kagaku Kenkyusho Co., Ltd., Nagoya, Aichi, Japan.
  • Ihara Y; Department of Medical Statistics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
  • Imai T; Department of Medical Statistics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
  • Morioka T; Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
  • Emoto M; Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Front Pharmacol ; 15: 1230562, 2024.
Article in En | MEDLINE | ID: mdl-38292940
ABSTRACT

Background:

Urate-lowering drugs (ULDs) have been approved for treatment of asymptomatic hyperuricemia and gout in Japan. Although serum urate levels and rates of gout onset are known to have seasonal variations, no survey results regarding the seasonality of ULD prescriptions for asymptomatic hyperuricemia and gout have been reported.

Methods:

A large-scale database of medical claims in Japan filed between January 2019 and December 2022 was accessed. In addition to total size of the recorded population for each month examined, the numbers of patients every month with newly prescribed ULDs for asymptomatic hyperuricemia and gout were noted, based on the International Classification of Diseases, 10th Revision, codes E79.0 and M10.

Results:

The results identified 201,008 patients with newly prescribed ULDs (median age 49.0 years, male 95.6%). Of those, 64.0% were prescribed ULDs for asymptomatic hyperuricemia and 36.0% for gout. The proportion of new ULD prescriptions was seasonal, with that significantly (p < 0.001) higher in summer (June-August) [risk ratio (RR) 1.322, 95% CI 1.218 to 1.436] and autumn (September-November) (RR 1.227, 95% CI 1.129-1.335) than in winter (December-February), whereas the proportion in spring (March-May) was not significantly different from winter. There was no significant difference after stratification by drug type (uric acid production inhibitor/uricosuric agent) or size of the medical institution, nor subgrouping by age or sex (p for interaction = 0.739, 0.727, 0.886, and 0.978, respectively). On the other hand, the proportions of new ULD prescriptions for asymptomatic hyperuricemia were significantly lower and for gout significantly higher in spring than winter, while those were similar in summer and autumn for both groups (p for interaction<0.001).

Conclusion:

The present findings indicate that new prescriptions for ULDs to treat asymptomatic hyperuricemia or gout in Japan show seasonal differences, with higher rates noted in summer and autumn as compared to winter.
Key words

Full text: 1 Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Front Pharmacol Year: 2024 Type: Article Affiliation country: Japan

Full text: 1 Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Front Pharmacol Year: 2024 Type: Article Affiliation country: Japan